SuperworthC4 Therapeutics revenue CCCC
Sales by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- $35M
- Latest quarter, Q2 FY26
- $6.6M
- +3% on a year earlier
- Fiscal year 2025
- $35.9M
- +1% on the year before
C4 Therapeutics' revenue was $35M over the twelve months to Jun 30, 2026, up 2% on a year earlier.
In its latest quarter, Q2 FY26, it was $6.6M, up 3% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $35.9M | +1% |
| FY2024 | $35.6M | +71% |
| FY2023 | $20.8M | −33% |
| FY2022 | $31.1M | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $6.6M | +3% | $35M | |
| Q1 FY26 | $6.2M | −15% | $34.9M | |
| Q4 FY25 | $11M | +113% | $35.9M | |
| Q3 FY25 | $11.2M | −27% | $30.1M | |
| Q2 FY25 | $6.5M | −46% | $34.2M | |
| Q1 FY25 | $7.2M | +138% | $39.8M | |
| Q4 FY24 | $5.2M | +59% | $35.6M | |
| Q3 FY24 | $15.4M | +39% | $33.7M | |
| Q2 FY24 | $12M | +351% | $29.4M | |
| Q1 FY24 | $3M | −19% | $20M | |
| Q4 FY23 | $3.3M | +14% | $20.8M | |
| Q3 FY23 | $11.1M | +64% | $20.3M |
Against its peers
Companies in Biotechnology nearest C4 Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CCCCC4 Therapeutics | $35M | +2% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| MGTXMeiraGTx | $397.5M | |
| VCELVericel | $306.3M | +23% a year |
| ADMAAdma Biologics | $512.3M | +8% a year |
| Peer median | $351.9M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on C4 Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.